Last Update: March 10, 2023, 4:07 pm IST
Reliance Life Sciences Chairman KV Subramaniam and IIT-Kanpur Director Professor Abhay Karandikar at the MoU exchange ceremony. (Special Arrangement/News18)
Reliance Life Sciences is developing several gene therapies to address unmet clinical needs. In addition, the company is also developing a range of human and animal health vaccines and mRNA products
The Indian Institute of Technology-Kanpur on Friday said it has licensed a gene therapy technology to Reliance Life Sciences Pvt Ltd, which has the potential to treat several hereditary eye diseases. IIT Kanpur’s gene therapy technology will be further developed as an indigenous product. Reliance Life Sciences.
Developed by Jayadharan Giridhar Rao and Shubham Maurya from the Department of Biological Sciences and Bioengineering (BSBE), IIT Kanpur, the patented technology modifies the genes of an organism to treat a genetic disorder, the institute said in a statement.
“Gene therapy using viral vectors has recently emerged as a powerful tool in the field of molecular medicine. We believe this technique can be used to treat Leber congenital amaurosis, an eye disease present from birth, and retinitis pigmentosa, a It holds great potential for the treatment of a variety of hereditary eye diseases, including the disease that causes a gradual loss of vision.
KV Subramaniam, chairman of Reliance Life Sciences, said the company would “take this innovative technology forward for commercialisation”.
IIT Kanpur said that this is the first time that technology related to gene therapy has been developed and transferred from an academic institution to a company in India.
Reliance Life Sciences is developing several gene therapies to address unmet clinical needs. In addition, the company is also developing a range of human and animal health vaccines and mRNA products, the statement said.
read all latest india news Here